tacrolimus

(redirected from Tacrolimus binding protein 1a)
Also found in: Dictionary.

tacrolimus

 [tak″ro-li´mus]
an immunosuppressant derived from a species of Streptomyces, having actions similar to those of cyclosporine; administered orally or intravenously to prevent rejection of organ transplants and topically to treat moderate to severe atopic dermatitis.

tacrolimus

/tac·ro·li·mus/ (tak″ro-li´mus) a macrolide immunosuppressant having actions similar to those of cyclosporine; used to prevent rejection of organ transplants; also used topically to treat moderate to severe atopic dermatitis.

tacrolimus

(tə-krō′lə-məs)
n.
An immunosuppressive drug produced by the actinomycete Streptomyces tsukubaensis, C44H69NO12, used in combination with corticosteroids to prevent rejection of organ transplants.

tacrolimus

an immunosuppressive drug that modifies biological response.
indications This drug is prescribed to suppress the immune system after transplantation of the liver or other organs and can be applied topically for the treatment of dermatitis unresponsive to other medications.
contraindications This drug should not be given to patients with allergy to tacrolimus or those receiving potassium-sparing diuretics, cycloSPORINE, or other immunosuppressive agents, with the exception of adrenal corticosteroids.
adverse effects The side effects most often reported include tremor, headache, diarrhea, hypertension, nausea, renal dysfunction, hyperglycemia, and increased risk of infection.

tacrolimus

FK506, Prograf Immunology An immunosuppressant that inhibits IL-2 synthesis and binding; it is similar to, and synergistic with, cyclosporine, up to 50-fold more immunosuppressive than cyclosporine; it is used in BM, kidney, liver, lung, and other transplants Adverse effects Neurotoxicity–tremor, seizures, white matter disease, headache, nausea, paresthesias of hands, feet, insomnia; nephrotoxicity, hyperglycemia, hirsutism, paresthesia, ↑ lipids, ↑ K+, HUS, ↓ Mg2+. Cf Cyclosporine.

tacrolimus

A potent immunosuppressant macrolide compound isolated from a bacterium. Tacrolimus is effective in reducing the risk of rejection of solid-organ transplants especially liver transplants. It has been successfully used as a monotherapy to prevent graft rejections and has virtually eliminated immunosuppression-related morbidity. It has also been found useful in ointment form for the treatment of moderate-to-severe atopic dermatitis in which it has been found as effective as strong topic steroids. Brand names are Prograf and Protopic.

immunosuppressants

Drugs that prevent or reduce the immune response. They are used in the treatment of a variety of severe inflammations such as uveitis, scleritis, keratoconjunctivitis sicca, Behçet's syndrome, sympathetic ophthalmia, and to prevent corneal graft rejection. They include the corticosteroids (e.g. prednisolone), ciclosporin (cyclosporine), tacrolimus, and cytotoxic agents (e.g. azathioprine, chlorambucil, cyclophosphamide, methotrexate). It must be noted that immunosuppressants render the patient more susceptible to infection because immunity is reduced.

tacrolimus (FK506),

n brand name: Prograf;
drug class: immunosuppressant;
action: inhibits T-lymphocyte activation leading to immunosuppression;
use: prophylaxis of organ rejection in patients receiving allogenic liver transplants.

tacrolimus

an immunosuppressive agent derived from Streptomyces tsukabaensis. It selectively binds FK-binding proteins and the complex inhibits calcineurin.